House Republicans Tell FDA to Stop Taking Chinese Clinical Trial Data on Faith

What happened: On August 21, 2026, Reps. John Moolenaar (R-MI), chairman of the House Select Committee on the Chinese Communist Party, and Ben Cline (R-VA) sent a letter to Acting FDA Commissioner Kyle Diamantas asking the agency to stop accepting clinical trial data generated in China unless the trial site has undergone an FDA audit within the prior 12 months, and to conduct a retrospective review of every product already approved in the US on the strength of Chinese-generated clinical data. The letter argues that “accepting Chinese clinical data poses real risks for patients” and warns that offshoring early-stage trials to China “risks rewarding a system that has shown it is willing to treat children’s deaths as an acceptable cost of faster, cheaper research.”

The three deaths behind the letter

The lawmakers cite three fatalities in separate China-based investigator-initiated gene-editing and cell-therapy trials, at least two of them involving children, none disclosed to regulators or the public in a timely way:

A boy with Duchenne muscular dystrophy died in August 2025 after receiving HuidaGene Therapeutics’ experimental CRISPR therapy HG302, developing acute respiratory distress syndrome from severe complement and cytokine activation. The company did not publicly acknowledge the death until August 5, 2026 — a full year later. CASRAI covered the underlying case as it emerged: a second undisclosed child death surfaces in a Chinese gene-editing trial, this time at HuidaGene.

A six-year-old girl with Snijders Blok-Campeau syndrome died seven days after gene-editing therapy at Xinhua Hospital in Shanghai in May 2025; researchers reportedly published findings from the trial without disclosing the fatal outcome. CASRAI covered the related institutional response: Shanghai Jiao Tong opens an investigation after an undisclosed death in a gene-editing trial.

RiboX Therapeutics reported the death of a systemic sclerosis patient following an experimental CAR-T cell therapy on August 9, 2026.

Why this matters beyond the three trials themselves

China now initiates more registered clinical trials annually than the United States, and Chinese-generated data has increasingly underpinned US approvals: by the lawmakers’ count, China produced 94 cancer drug approvals between 2020 and 2025 against 87 for the US over the same period. A large share of that activity runs through investigator-initiated trials (IITs) rather than sponsor-run, FDA-inspected studies — a regulatory pathway with materially lighter oversight than an FDA IND. If FDA adopts anything close to what the letter asks, sponsors currently relying on China-sourced foreign clinical data to support a US submission should expect one of two outcomes: a requirement to produce evidence of a recent FDA audit of the specific trial site, or exclusion of that dataset from the submission entirely.

What sponsors and research offices should do now

Inventory any submission-supporting foreign clinical data sourced from China, and separately flag which of it comes from FDA-inspected sites versus investigator-initiated trials that have never been audited. This is the fault line the letter draws.

Revisit sponsor oversight documentation for multi-region trials with a China arm. CASRAI’s dictionary entry on ICH E6(R2) Section 5 sponsor obligations covers the oversight and vendor-qualification duties that become the first thing scrutinized if FDA tightens acceptance criteria for foreign data.

If your institution is weighing whether a first-in-human study needs a US IND versus proceeding as a foreign IIT, CASRAI’s IND application decision tree walks through that threshold question, which is precisely the distinction this letter is trying to make FDA police more aggressively.

The letter is a request, not a rulemaking, and Diamantas has not yet issued a public response as of this writing. But it follows a House Select Committee on the CCP investigation opened earlier this year into five drugmakers over their China trial arrangements, so institutions with active or planned China-based trial sites should treat this as a live regulatory-risk signal rather than a one-off letter, and start the documentation work now rather than after a policy lands.